Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 16/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.48 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171371 | 0.90 | TRPA1 (0.79) | TRPA1MAPTSMN1; SMN2LMNA | |
| SCHEMBL609734 | 0.90 | TRPA1 (0.83) | TRPA1MAPTTRPV4TRPV3SMN1; SMN2 | |
| SCHEMBL10171817 | 0.87 | TRPA1 (0.72) | TRPA1MAPT | |
| SCHEMBL2696517 | 0.87 | TRPA1 (0.73) | TRPA1MAPTTRPV4SMN1; SMN2 | |
| SCHEMBL10171777 | 0.84 | TRPA1 (0.65) | TRPA1MAPT | |
| SCHEMBL15746154 | 0.84 | TRPA1 (0.84) | TRPA1MAPTSMN1; SMN2LMNA | |
| SCHEMBL15746155 | 0.83 | TRPA1 (0.62) | TRPA1MAPTTRPV4 | |
| SCHEMBL612868 | 0.82 | TRPA1 (0.69) | TRPA1MAPTTRPV4SMN1; SMN2 | |
| SCHEMBL2696346 | 0.81 | MAPT (0.69) | TRPA1MAPTTRPV4SMN1; SMN2 | |
| SCHEMBL612857 | 0.81 | TRPA1 (0.73) | TRPA1MAPTTRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | TRPA1 1/4885MAPT 2007/4885TRPV4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.